Trulance (palovarotene) is a medication available in a 3 mg tablet formulation. It is a retinoic acid receptor gamma (RARγ) agonist.
What is Trulance used for?
Trulance is indicated for the treatment of fibrodysplasia ossificans progressiva (FOP) in adult and pediatric patients [1]. FOP is a rare genetic disorder characterized by progressive heterotopic ossification, where bone forms in soft tissues like muscles and tendons [1].
How does Trulance work?
Trulance targets the specific signaling pathway involved in the abnormal bone formation seen in FOP. By activating the retinoic acid receptor gamma, it aims to reduce the inflammation and heterotopic ossification associated with the condition [1].
When does Trulance's patent expire?
Information regarding the patent expiry for Trulance is available on DrugPatentWatch.com. This resource provides details on patent status and anticipated exclusivity periods for various medications [2]. For specific patent expiration dates, please refer to DrugPatentWatch.com [2].
What are the potential side effects of Trulance?
Common side effects reported with Trulance include dry mouth, diarrhea, nausea, abdominal pain, and dry skin [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is Trulance administered?
Trulance is taken orally, typically once daily [1]. The dosage and frequency may be adjusted by a healthcare professional based on individual patient needs and response to treatment.
Where can I find more information about Trulance's patent and exclusivity?
DrugPatentWatch.com offers comprehensive data on drug patents and market exclusivity. You can search for Trulance on their platform to find detailed information on its patent landscape [2].
Are there other treatments for fibrodysplasia ossificans progressiva?
Currently, Trulance is one of the approved treatments for FOP. Research and development for other therapeutic approaches for FOP are ongoing, but Trulance represents a significant advancement in managing the condition [1].
*
**Sources:
1. https://www.trulance.com/
2. https://www.drugpatentwatch.com/